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Abstract
Intravascular ultrasound is a catheter-based imaging modality that was developed to investigate the condition of coronary
arteries and assess the vulnerability of coronary atherosclerotic plaques in particular. Since its introduction in the clinic 20
years ago, use of intravascular ultrasound innovation has been relatively limited. Intravascular ultrasound remains a niche
technology; its clinical practice did not vastly expand, except in Japan, where intravascular ultrasound is an appraised tool
for guiding percutaneous coronary interventions. In this qualitative research study, we follow scholarship on the sociology
of innovation in exploring both the current adoption practices and perspectives on the future of intravascular ultrasound.
We conducted a survey of biomedical experts with experience in the technology, the practice, and the commercialization of
intravascular ultrasound. The collected information enabled us to map intravascular ultrasound controversies as well as to
outline the dynamics of the international network of experts that generates intravascular ultrasound innovations and uses
intravascular ultrasound technologies. While the technology is praised for its capacity to measure coronary atherosclerotic
plaque morphology and is steadily used in clinical research, the lack of demonstrated benefits of intravascular ultrasound
guided coronary interventions emerges as the strongest factor that prevents its expansion. Furthermore, most of the
controversies identified were external to intravascular ultrasound technology itself, meaning that decision making at the
industrial, financial and regulatory levels are likely to determine the future of intravascular ultrasound. In light of opinions
from the responding experts’, a wider adoption of intravascular ultrasound as a stand-alone imaging modality seems rather
uncertain, but the appeal for this technology may be renewed by improving image quality and through combination with
complementary imaging modalities.
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Introduction
Tremendous advances occurred during the last 40 years in the
field of medical imaging of the heart and the coronary vasculature,
triggered by the increasing need to reduce acute myocardial
infarctions. The intravascular imaging route led to the develop-
ment of X-ray angiography in the 1960’s, balloon angioplasty and
related techniques in the late 1970’s and early 1980’s. Meanwhile,
in the early 1970’s, academic research programs focused on
developing two-dimensional real-time ultrasound imaging of the
heart, transferring in particular knowledge from underwater
acoustics to medicine [1]. This noninvasive route led to
echocardiography, an imaging modality acclaimed for its radiation
free nature but lacking the resolution to image the coronary
vasculature.
The need for a technique able to provide high resolution images
of diseased coronary artery wall structures, referred to as
vulnerable plaques [2] and primarily responsible for myocardial
infarctions, arose in the early 1990’s when false-negative coronary
angiography cases became evident [3]. Intravascular ultrasound
(IVUS) is a catheter-based echocardiography modality that was
patented in 1972 [4] and further developed to investigate the
status of the coronary artery wall. The tip of an IVUS catheter
incorporates a single piezoelectric transducer (40 to 60 MHz
frequency range) or a circular array of transducers (20 MHz) to
generate circular cross sectional images of the arterial wall,
perpendicular to the longitudinal artery axis. Single transducer
IVUS images are acquired by mechanically rotating the
transducer over 360 degrees, whereas in circular array IVUS the
ultrasound beam is steered electronically. The resolution of IVUS
images is of the order of 100 mm in the axial direction, 300 mm in
the lateral direction [5], and IVUS imaging depth typically ranges
from 5 to 10 mm. IVUS technology has played an important role
in the standardization of balloon angioplasty and stent treatments.
Before intervention, IVUS can provide the artery lumen diameter,
the plaque morphology and burden [6] thanks to the delineation
of the external elastic membrane, and can be used to select optimal
stent dimensions. Post intervention, IVUS is also useful to control
stent apposition and possible complications. In addition, IVUS
technology proved to be very useful in cardiovascular research.
Since plaque progression and regression can be accurately
measured with IVUS, the efficacy of new cardiovascular therapies
on plaque volume can be quantified. IVUS also serves as gold
standard for the evaluation of new intravascular modalities. Next
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to the estimation of plaque burden, the most valued IVUS
function is calcium detection. Unfortunately, predicting the risk for
future acute cardiovascular events requires knowledge of plaque
composition [7], which is not provided by conventional IVUS.
Several IVUS signal processing techniques have been developed at
an academic level to augment IVUS capabilities in detecting and
characterizing coronary artery plaques at risk [8,9] but failed to
reach clinical practice so far.
Looking back, the realization of IVUS is undoubtedly a
technical success. Twenty years after its introduction in the clinic
in the early 1990’s, IVUS technology continues to bring scientific
insight into the pathophysiology of the coronary artery disease and
helps guiding percutaneous coronary interventions. To date, the
noninvasive imaging techniques capable of identifying coronary
artery wall lesions are magnetic resonance imaging (MRI) and
multi-slice computed tomography (MSCT), but their resolution
remains inferior to in situ catheter techniques. Minimally invasive
imaging techniques include coronary angiography, angioscopy,
IVUS, intravascular optical coherence tomography (OCT), the
combination of near infrared reflectance spectroscopy (NIRS) with
IVUS [10]. OCT in particular has emerged as a rival for IVUS by
generating more superficial but higher resolution images of the
arterial wall.
Surprisingly, IVUS innovation appears relatively limited since
its introduction in the clinic, especially in terms of image quality.
Significant academic innovations such as IVUS flow [11,12],
IVUS palpography [8,13], harmonic IVUS [14,15] and contrast-
enhanced IVUS [9,16] were to date not taken up by industry.
Furthermore, IVUS remains a niche technology, whose clinical
practice did not vastly expand nor disappear. IVUS reimburse-
ment varies considerably worldwide which reveals a contrasted
adoption of IVUS. In Japan, IVUS is reimbursed separately since
1994, even for diagnostic use. In the United States, IVUS is not
reimbursed but procedure codes leave enough room for IVUS
utilization where necessary. In the rest of the world, there is no
separate reimbursement for IVUS. IVUS market penetration
worldwide follows accordingly.
Following scholarship in sociology of innovations, we were
interested in understanding both the reasons for current adoption
practices and prospects for further adoption or development of the
technology in the future. As part of this, we sought to outline issues
related to the technology, which are often referred to as
‘controversies’ [17], meaning that they can still be disputed,
negotiated, etc. and practice, whereby the end result is still
unknown. Understanding the various issues at stake for the
respondents is important because how these further develop in
practice can shape the future of the technology. To identify these
issues, we took a qualitative approach. This approach combined a
survey of experts currently generating innovations and/or using
IVUS technologies with a social network analysis of their
interactions.
Materials and Methods
To outline the dynamics of the network of experts that generates
IVUS innovations and uses IVUS technologies, we conducted a
survey of biomedical experts with experience in the technology
and practice of IVUS. To that end, we selected a deliberative
sample of potential respondents: a representative group of 49
experts dealing with the question of IVUS innovation or adjacent
fields. Potential respondents were identified through publications
in the field and confirmed through an expert check (Professor van
der Steen, head of the Biomedical Engineering Department of the
Thorax Centre, Erasmus University Medical Center, the Nether-
lands). Identified experts comprised interventional cardiologists,
academic and corporate engineers, corporate leaders and public
and private funders. For ethical considerations, the questionnaire
data were collected under the agreement that data sourcing was
kept anonymous. Questionnaire answers were pooled, randomized
and analyzed anonymously. Participants were aware that their
responses would be used in this study and that their company
names may be included.
Survey design
We developed a questionnaire [18] with a combination of open
and closed questions on IVUS innovation and refined it through
face-to-face interviews with three experts. After revision, the
questionnaire was issued to all other experts. The questionnaire
started with two open questions about coronary atherosclerosis
diagnostic in humans: ‘‘What is the best method available to diagnose
human coronary atherosclerosis?’’ and ‘‘What would be an ideal technique to
diagnose coronary arteries?’’. The first question permitted to review the
coronary diagnostic tools that are currently appraised. The second
question aimed at highlighting the limitations of existing diagnostic
tools and identifying future diagnostic solutions with strong
potential in the respondents’ opinion. The questionnaire contin-
ued with questions focused on IVUS. To characterize the
homogeneity of the respondents, we asked them to rate (from 0
- not so much, to 10 - extensive) their technical, clinical and
market knowledge representation of IVUS. We collected their
opinions on the advantages and disadvantages of IVUS. Next
came two central questions: the room IVUS technology has left for
improvement (to be rated from 0 - no room, to 10 - lots of room),
and the likelihood of the existence of IVUS 20 years from now (to
be rated from 0 – uncertain, to 10 - certain). These questions were
inserted to quantify the future perspective of IVUS technology in
the respondents’ opinion. Next, we asked what the reimbursement
procedure was for new medical devices in the respondent’s country
of residence before to specifically address the status of IVUS
reimbursement. Then, we asked what were the prevailing factors
that could explain the continuous but limited clinical utilization of
IVUS in the respondents’ opinion. Interventional cardiologists
were specifically asked how IVUS helps them complete the regular
tasks of their job. All these questions were inserted to collect
material explaining the current adoption of IVUS. The last part
contained of questions on the additional factors likely to impact
IVUS innovation (e.g. educational efforts in IVUS, role of patents,
and competition between experts in the IVUS market). Finally, we
provided room for further comments related to IVUS technology
that the respondents might want to share.
Network analysis
In the second part of the questionnaire, we asked the
respondents to indicate the frequency and nature of their
interaction with other identified experts. We analyzed the level
of interaction among our deliberative sample of respondents using
the social network analysis software UCINET (Harvard Univer-
sity, Boston, USA) [19]. A clique analysis was performed,
assembling groups of four members or more who declared
symmetric interactions [20]. Subsequently, we proceeded to a
hierarchical cluster analysis of the respondents’ adjacency in the
network: an algorithm ordered the respondents hierarchically
based on their level of similarity (amount of clique memberships
shared by pairs of experts) and their proximity in the network. We
displayed the result as a hierarchical clustering tree diagram using
UCINET (see Figure 1). Having registered the bonds between
experts, which informs on the professional network architecture, as
well as the respondents’ opinions on IVUS technology, we could
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map IVUS controversies and discuss their implications for the
future of IVUS with respect to the position of the respondents in
the network. It is important to realize that the individuals who
contributed to this study represent a part of a bigger professional
network, which is a limitation of this study. However, we postulate
that the group of respondents that was surveyed is representative
of the hierarchies and opinions present in the community of
experts that generates IVUS innovations and uses IVUS
technologies.
Description of the respondents
With the initial list of potential respondents, 38 international
institutions were represented (20 American, 9 Dutch, 3 Canadian,
2 Japanese, 2 French, 1 German, and 1 South Korean). The list
comprised the following types of respondents:
- Fifteen corporate leaders, encompassing IVUS companies
(Boston Scientific, Volcano, Terumo, Infraredx, Silicon Valley
Medical Instruments and Colibri Technologies), a company
fostering competing intravascular technologies, two general
medical ultrasound companies, and a clinical research organiza-
tion with experience in interventional cardiology.
- Fourteen cardiologists conducting clinical research involving
IVUS or practicing IVUS-guided percutaneous coronary inter-
ventions (PCI). The group identified comprised key opinion
leaders as well as international cardiologists in activity performing
IVUS related research.
- Ten engineers involved with IVUS innovation or related fields.
This included two academic engineers who filed constitutive IVUS
inventions, four academic engineers currently in activity as well as
four corporate engineers.
- Ten funders involved with IVUS innovation or related fields.
Six were public funders and four private funders. Public funders
represented public research organizations, public technology
foundations. Private funders encompassed private technology
foundations and investment firms.
Of the initial 49 experts, 23 returned a completed questionnaire.
We analyzed the responses by first reassigning them into pertinent
categories. Among cardiologists (8 respondents), a distinction was
made between opinion-leading cardiologists (3 respondents) and
academic IVUS users (5 respondents), based on internal knowl-
edge of the field of IVUS and top authors tracking on a biomedical
experts platform. Among corporate leaders (6 respondents), a
distinction was made between IVUS companies (4 respondents)
and related field companies (2 respondents). Public and Private
funders were merged in a single group because of the limited
contributions (2 respondents). Finally, engineers (7 respondents)
were divided into academic (5 respondents) or corporate engineers
(2 respondents).
For figure and citation purposes, we labeled IVUS corporate
leaders as IVUS Corp Leader, corporate leaders in adjacent fields as
Figure 1. Respondents’ perception of intravascular ultrasound resolution. Early experts are indicated with a star. Experts that were the least
central in the network, who declared a limited level of interaction with other members, appear at the bottom of the diagram. The diagram can be
subdivided as follows: a base of peripheral experts that are the least central in the network, a middle group, including early IVUS experts, with an
intermediate centrality level, and finally the leading group of the network gathering the most central experts.
doi:10.1371/journal.pone.0097215.g001
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Adj Corp Leader, opinion leading cardiologists as Lead Cardiol,
academic IVUS users as Acad IVUS Users, academic engineers as
Acad Eng, corporate engineers as Corp Eng and funders as Funder.
Results
Self-characterization of the respondents
Overall, respondents demonstrated a homogeneously high
technical knowledge (total average of 8.1) and clinical knowledge
(total average of 7.6) of IVUS, indicating that we successfully
surveyed experts involved at the technical and medical interface of
IVUS. The technical knowledge was well aligned among all
categories of experts. Engineers reported a deficit in clinical
knowledge (average of 6.0), below cardiologists and corporate
leaders, indicating that they do not perceive themselves as medical
specialists. Respondents’ market knowledge appeared to be more
widespread (total average of 7.0), above average for opinion-
leading cardiologists and corporate leaders and below average for
academic IVUS users. The experts’ knowledge representation of
IVUS reimbursement policies worldwide was the lowest (total
average of 5.0). IVUS corporate leaders and corporate leaders of
related fields were above average while corporate engineers and
funders were below. Cardiologists and academic engineers were
average. Corporate leaders naturally appeared to be more focused
than the rest on the non-technical factors that governing the
development of medical technologies.
Historical context of IVUS introduction
Twenty years elapsed between the registration of the first IVUS
patent in 1972 [4] and its transfer to clinical research in the early
1990’s [21,22], when the technology caught the attention of
interventional cardiologists willing to visualize coronary artery wall
lesions. This was clear, for example, in this response from a
European respondent:
‘‘As the big worry for cardiac echography was to see through
the ribs, the idea of a phased array catheter was suggested.
But in the meantime, the external linear array proved to be
successful. People could see the heart and babies. Since the
noninvasive approach worked, people forgot about the
phased array catheter until the early nineties, when the need
for a high resolution technique able to characterize coronary
artery lesions emerged.’’ (Acad Eng)
The introduction of IVUS as a high tech medical device
followed a classical path. It first started as an academic engineering
project aiming at developing intracardiac echocardiography in
real time. IVUS technology eventually found light as a high
resolution tool to characterize coronary artery lesions, as a result of
the academic collaboration of cardiologists and engineers. This
was clear, for example, in this response about the advantages of
IVUS from Canadian respondent:
‘‘It [IVUS] has good penetration through blood and soft
tissue, enabling estimation of vessel dimension, vessel
remodeling, and plaque burden with high sensitivity and
specificity in identifying coronary calcifications’’. (Acad Eng)
The second phase of IVUS introduction was its adoption by
industry. The industrial development and aim given to IVUS was
largely shaped by Boston Scientific. This is evident, for example, in
this response from the US:
‘‘In the first 10 years, Mansfield/Boston Scientific and CVIS
were alone; then BSC bought CVIS and merged their
platform.’’ (IVUS Corp Leader)
As Boston scientific is primarily a stent manufacturer, IVUS
holds an adjacent technology position within the company
portfolio. IVUS was positioned as a percutaneous coronary
intervention (PCI) guidance tool, allowing for peri-interventional
planning and assessment of complications. This role is clear, for
example, in the response of an interventional cardiologist who
explains how IVUS helps him complete the regular tasks of his job:
‘‘IVUS-guided PCI:
1. PRE: Plaque assessment, luminal diameters, stent length sizing.
2. INTRA: Stent apposition, re-entry in dissected planes, ante/
retrograde chronic total occlusion (CTO).
3. POST: thrombus, edge prolapse, dissection, etc.’’ (Lead Cardiol)
This tells us that the use of IVUS evolved from a research
diagnostic tool to a PCI intervention guidance tool. It raises the
question of the role for intracoronary imaging technologies. To
date, IVUS technology is perceived as well aligned within the
product portfolio of IVUS companies. This was reported in this
response from the US:
‘‘All companies try to create a coronary artery imaging
platform. For Boston Scientific and Terumo, IVUS is an
adjacent market. For Volcano, Infraredx, it is a central
market.’’ (Funder)
The third stage of the introduction of IVUS is its reimburse-
ment via public health policy. Overall, the reimbursement process
for a new medical device consists in the following: evidence-based
medicine must prove benefits in using the technology. Subse-
quently, randomized clinical trials are to be conducted to
determine whether the technology leads to an improved effective-
ness in terms of patient outcome as well as a superior cost-
effectiveness than the standard of care. The reality of IVUS
reimbursement appears contrasted. In the US, the situation was
reported as follows:
‘‘There is no separate reimbursement for IVUS and it must
be bundled into the existing Diagnosis-related group (DRG)
for the specific coronary intervention. A separate set of cost-
effectiveness and clinical utility data would be required to
create stand-alone IVUS reimbursement’’ (IVUS Corp Leader)
This indicates that IVUS only partially fulfills the usual
requirements for the reimbursement of a new device in the
United States. Most notably, it appears that the technology has
failed to demonstrate clinical utility. Yet, several respondents
pointed at the clear dissymmetry in the reimbursement of IVUS
that exists worldwide. This was clear, for example, in this response
from the US:
‘‘Separate reimbursement exists in Japan, where IVUS
penetration is widely viewed as the deepest in any part of the
world. This is not circumstantial. The second highest major
market penetration is in the US, where it is not reimbursed
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separately but in which specific procedure codes do leave
enough room for IVUS utilization where necessary. The
lowest penetration exists in EU and Asia/Latin America
markets where per-procedure economics are tightest and no
separate reimbursement exists. Thus, while there is
undoubtedly strong clinical belief in the utility of IVUS,
there is an undeniable correlation between where that
clinical belief manifests and where the economic policies are
most accommodating.’’ (IVUS Corp Leader)
Japan’s separate reimbursement of IVUS is unique worldwide
and seems to be the result of a stronger belief in the utility of IVUS
interventional cardiology practice. Nonetheless, the status of IVUS
reimbursement is a strong indicator of a contrasted acceptance of
the technology and reveals that IVUS must be engaged into a set
of controversies.
Open debates surrounding IVUS technology
By reviewing the contributors’ answers, we identified six
controversies revolving around IVUS technology; a controversy
being defined as a debate surrounding a technique, for which the
outcome has not yet been determined [17,23]. The controversies
identified are reported in Table 1.
- The first controversy concerns the invasive nature of IVUS. It
opposes experts who perceive invasiveness as a limitation, e.g. by
preventing the screening of asymptomatic patients, to experts who
relativize the minimal invasiveness of IVUS in light of the
interventional nature of their job.
- The second controversy identified concerns the resolution of
IVUS imaging. It opposes experts who perceive IVUS resolution
as insufficient to detect important features of atherosclerotic
plaques (e.g. thrombi, thin cap fibroatheroma, plaque composi-
tion) and/or consider IVUS images as difficult to interpret, to
experts who praise the sufficient clarity of IVUS whose resolution
provides well validated quantitative measurements of atheroscle-
rotic plaques (e.g. size and shape of coronary lesions, residual
lumen, calcium detection, clear images of stent struts).
- The third controversy concerns the practicability of IVUS as a
diagnostic tool. It opposes experts who consider that IVUS is an
expensive and late diagnostic solution (restricted to patients who
already need an intervention) which is tedious to analyze, to
experts who praise the local knowledge of the plaque provided by
IVUS and therefore its prognostic value, as well as the fact that
IVUS is relatively quick to use.
- The fourth controversy concerns the utility of IVUS as a
percutaneous coronary intervention (PCI) guidance tool. It
opposes experts considering that IVUS has a limited impact on
clinical decision making and failed to prove clinical benefits in
terms of PCI treatment outcome, to experts who consider that
IVUS improves safety overall by resolving ambiguous anatomy on
angiograms (for example at the left main coronary artery), permits
the adequate selection of stent landing zones and stent size, and
allows for the evaluation of post-intervention complications.
- The fifth controversy concerns the impact of IVUS
reimbursement on IVUS utilization worldwide. It opposes experts
who consider that IVUS current reimbursement leaves enough
room for an appropriate use and that expansion is primarily
limited by the lack of demonstrated IVUS benefits, to experts who
consider that a separate reimbursement of IVUS, even for
diagnostic use, would favor its development as observed in Japan.
- The sixth controversy concerned the means invested in the
education of IVUS experts. In light of the absence of clearly
Table 1. Ongoing IVUS controversies conveyed by the respondents.
Controversy Positive responses Negative responses
Invasiveness of IVUS ‘‘Minimally invasive’’; ‘‘The technique is invasive but I am an
interventional cardiologist. IVUS takes 30 seconds’’
‘‘IVUS is very invasive to find the site of interest’’; ‘‘A major
disadvantage is that IVUS is invasive’’
Resolution of IVUS ‘‘High resolution and similarity to pathology’’; ‘‘It has good
penetration through blood and soft tissue, enabling estimation
of vessel dimension, vessel remodeling, and plaque burden
with high sensitivity and specificity in identifying coronary
calcifications’’
‘‘Unacceptably poor resolution’’; ‘‘Resolution is not enough for
some particular purpose (Thin Cap Fibroatheroma)’’
Usefulness of IVUS as
diagnostic tool
‘‘In order to understand the local problem, a catheter is the
best’’; ‘‘Large investigation range in combination with pull-
back’’; ‘‘Relatively quick, you can see obstruction, size and
shape of the lesion (morphology)’’; ‘‘Well validated quantitative
measurements, many related outcome evidence by IVUS
measurements (example, minimum stent area to predict future
revascularization), easy to learn/use’’; ‘‘Resolves ambiguous
anatomy on angiogram, especially at left main’’
‘‘Intra-coronary imaging is too invasive and too late to use’’;
‘‘most information not needed in daily practice unless
complication’’; ‘‘Lack of clarity of the images (I think I know what
I’m looking at but not entirely sure) and the difficulty of acquiring
those images’’; ‘‘A catheter does not provide a complete view of
the vascular tree’’
Usefulness of IVUS as PCI
guidance tool
‘‘Inadequacy of angiography to guide clinical decision making
in complex anatomy’’; ‘‘Clinical trials have shown that the use
of IVUS is reasonable during PCI for several indications. The
medical literature continues to demonstrate limitation of
angiographic-only guidance for PCI’’
‘‘Clinical impact on decision making is limited’’; ‘‘There is no large
clinical trial to show the benefit of using IVUS’’; ‘‘Absence of





‘‘Separate reimbursement exists in Japan, where IVUS
penetration is widely viewed as the deepest in any part of the
world. This is not circumstantial’’; ‘‘Japan has reimbursement
even for diagnostic IVUS. If not, the usage will decrease to
half of now’’
‘‘Reimbursable for appropriate use’’; ‘‘I think the biggest limit is
the lack of investment in academic research’’; ‘‘It affects the
clinical use. Institutions like the Thoraxcenter simply supply the
difference, but in peripheral hospitals the clinical use is affected.
The IVUS innovation is an academic/industrial process and is
financed by other means’’
Educational efforts in IVUS ‘‘A focused educational program is needed for realizing the
potential of this technique’’
‘‘Today it’s a niche technology, teaching efforts questionable
given poor penetration’’
doi:10.1371/journal.pone.0097215.t001
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demonstrated clinical benefits in using IVUS, some experts
consider that enough educational efforts are consented (live cases
at conferences, publications, experts visits), while others consider
that because IVUS technology is not exploited at its full potential,
a global educational effort is required (e.g. exposure of cardiol-
ogists in training, creation of a certification program, online
consulting systems).
It is interesting to note that only one of the six controversies
identified - the ongoing debate on IVUS resolution - was intrinsic
to the technology itself. All others appeared as peripheral debates
surrounding IVUS practice and questioning aspects of interven-
tional cardiology practice in general. Nonetheless, the amount of
controversies identified is not negligible and raises the question of
the future of IVUS, especially since the field of intracoronary
imaging has become more competitive with the introduction of
OCT. In particular, the role of intravascular imaging seems to be
questioned: is the goal to mimic histology, to perform prognostic
imaging and/or to provide procedure guidance?
Mapping IVUS controversies
In order to analyze controversies by taking into account the
social network dynamics, we projected the respondents’ opinions
on the UCINET tree diagram (Methods section). In Figure 1, we
projected the opinions of the respondents who mentioned
‘‘resolution’’ when answering to the question of the disadvantages
of IVUS. By doing so, we mapped the ongoing debate on the
resolution of IVUS imaging (identified earlier as the only one
intrinsic to the technology of IVUS). It appeared that the six most
central experts in the network perceive IVUS resolution as
insufficient. Interestingly, the figure reveals that none of the
historic experts (marked with a star in the figure) cited resolution as
a disadvantage of IVUS. From their perspective, IVUS was
introduced as a high resolution technique, filling a void in
interventional cardiology. Figure 1 displays therefore the evolution
of the debate on resolution since the introduction of IVUS. We
know that IVUS image quality did not drastically change since its
introduction. Still it changed from high to low at the advent of
OCT. A clear change in understanding of what ‘‘high resolution’’
means is observed, independent from the developmental path of
IVUS technology: it indicates a mutual shaping between
technology and society.
Future perspective for IVUS technology
When looking at the distribution of the answers of the
respondents to the two central questions (the room for improve-
ment left for IVUS technology and the perspective of existence in
20 years), we observed a singular double-peak distribution
(Figure 2).
This result clearly indicates that two populations coexist in the
IVUS network surveyed, one optimistic and one pessimistic about
the technology perspective. We rearranged the responses into two
categories, the positive opinions (values above 6) and the negative
opinions (values below 6). Academic engineers were the most
optimistic when rating the room for improvement that IVUS
technology has (average of 7.8), which is natural considering that
they are professionally invested in IVUS innovation. Academic
IVUS users were optimistic as well (7.3) followed by IVUS
corporate leaders (6.8). On the contrary, corporate engineers
appeared pessimistic (4.5) while other corporate leaders were the
most pessimistic (1.5). Logically, it appears that the judgment on
the room for improvement of IVUS is directly dependent on the
degree of investment the experts have in IVUS: engineers and
corporate leaders involved with other intravascular technologies
were negative about the innovation potential that IVUS has left.
Results were projected on the tree diagram in Figure 3, showing
that historic experts emerge as the principal subgroup sharing a
positive opinion about the room for innovation left for IVUS
technology. Note that most central experts, who are currently
professional active, conveyed a rather negative opinion.
Concerning the existence of IVUS in 20 years, the optimistic
group gathered academic IVUS users (7.1), academic engineers
(6.6) and IVUS corporate leaders (6.5). The pessimistic group was
made of the opinion-leading cardiologists (4.3), other corporate
leaders (4.0) and funders (3.3). Engineers and IVUS corporate
leaders were convinced of the future of the technology. Converse-
ly, opinion-leading cardiologists and funders were skeptical about
the future of IVUS. Again, historic experts shared an optimistic
vision of the future of IVUS as for the previous question. Central
experts in the network appeared more balanced. Experts with a
low centrality (potentially less tied to IVUS) were rather
pessimistic.
When the answers to both questions are coupled, it appears that
academic engineers, academic IVUS users and IVUS corporate
leaders share a globally optimistic view, whereas opinion-leading
cardiologists, other corporate leaders and funders shared a globally
pessimistic view. Therefore, a major conclusion is that opinion-
leading cardiologists and funders, who orientate innovation due to
their position, disclosed a pessimistic opinion of the existence of
IVUS technology 20 years from now. Their regard on the future
of the technology was clearly exposed, for example, in this
response from the US:
‘‘In my opinion, the use of IVUS only makes sense as part of
conventional angioplasty. If it were incorporated as part of
the procedure, then there would not be a need for a second
invasive procedure. However, the fact that IVUS is invasive
may limit its capability for growth, especially if non-invasive
MRI and CT coronary diagnostic imaging capabilities reach
the point that they become more attractive, competitive
diagnostic procedures. This may be possible in the near
future, and might decrease the need for invasive diagnostic
procedures like IVUS.
A more important consideration would be the results of
comparative effectiveness studies of IVUS, compared to conven-
tional angioplasty. If it could be proved that IVUS increased
longevity or decreased complications, this would contribute
toward making this procedure more attractive to practitioners’’
(Funder)
Discussion
This study demonstrates that the development and positioning
of IVUS, in the high-tech environment of interventional cardiol-
ogy adjunctive devices, is shaped by co-developing controversies
surrounding the technology. We questioned why IVUS neither
expanded nor disappeared since its introduction 40 years ago. The
capacity of IVUS to estimate total coronary plaque burden was
almost unanimously reported by the respondents and appears as
the principal advantage of IVUS. IVUS is the only clinical tool
capable of measuring plaque burden in vivo [24] and was shown
to be a predictor of major adverse cardiovascular events [6]. For
this reason, the technology is praised in cardiovascular research
since it allows for longitudinal studies of atherosclerosis progres-
sion. IVUS can also rely on an extensive publication database and
has become the gold standard to compare to when introducing a
new intravascular imaging technology. Therefore, one possible
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explanation is that it is the utilization of IVUS in cardiovascular
research that kept the technology running in academic medical
centers.
On the other hand, the absence of good reimbursement was
clearly reported as directly limiting the clinical use of IVUS (or
would affect its use in the case of Japan). But respondents from the
United States, Europe and Japan alike also reported that the
Figure 2. Future perspective of intravascular ultrasound according to the respondents.
doi:10.1371/journal.pone.0097215.g002
Figure 3. Room for innovation in intravascular ultrasound according to the respondents. Early experts are indicated with a star. Least
central experts in the network appear at the bottom of the diagram and most central experts at the top.
doi:10.1371/journal.pone.0097215.g003
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creation of stand-alone reimbursement for a medical device
requires cost-effectiveness and clinical utility data. Therefore, we
can pose the question whether it is the lack of demonstrated
medical evidence in favor of IVUS technology that prevented the
creation of a stand-alone IVUS reimbursement, with the exception
of Japan where the technology was reimbursed in 1994.
The case of IVUS reimbursement in Japan can be explained by
two converging factors. First, an early interest for IVUS
technology (in 1993 IVUS was used in Japanese hospitals for
clinical research), which was originally offering both the highest
resolution available in interventional cardiology and validated
quantitative and outcome related measurements (e.g. ‘‘minimum
stent area to predict future vascularization’’). Second, a reim-
bursement accreditation procedure for approving a new medical
device that is ‘‘not inferior to existing alternatives but does not
have to be superior in every aspect’’. Other countries adopted a
wait-and-see stance, as a stand-alone IVUS reimbursement
requires a set of ‘‘cost-effectiveness and clinical utility data’’.
Penetration of IVUS is the lowest in Europe, Latin America and
Asia where reimbursement policies are the least accommodating.
It is the combination of a strong belief in the clinical utility of
IVUS and an accommodating economic policy that fosters the use
of the technology. A Japanese respondent reported that if IVUS
was not reimbursed in Japan, its use would be halved compared to
now. Ulucanlar et al. [25] recently argued that ‘technology
identities’ e.g. their novelty, effectiveness, utility, risks and
requirements are socially constructed and shape technology
adoption. Here we show in the case in the particular case of
IVUS that the ‘identity’ of a given technology can vary
geographically.
Several other lessons relevant for both the future of IVUS and
the introduction of new intracoronary imaging techniques can be
learned from this sociological study of IVUS innovation. We
observed that the only controversy intrinsic to IVUS technology
was the debate on IVUS resolution. It is important to analyze at
the architecture of the network of IVUS experts surveyed when
evaluating the implications of this controversy. The tree diagram
(Figure 1) can be subdivided in three groups: a base of peripheral
experts that are the least central in the network, a middle group of
early IVUS experts with an intermediate centrality level and
finally, the leading group of the network gathering the most central
experts. Experts at the top of the diagram are likely to be in close
collaboration and/or competition with each other and to be the
most deeply involved with IVUS or adjacent technologies.
Furthermore, their point of view is dominant because of their
central position in the network. But they are also likely to have the
highest interest in promoting a given imaging modality. Since the
six most central experts in this survey are all indicating that IVUS
resolution is insufficient, we can assume that improvements are
mandatory for the future of the technology. Note that a significant
enhancement in IVUS image quality could be achieved by
improving IVUS lateral resolution, currently three times worse
than axial resolution [5]. This strategy was investigated academ-
ically by Chandrana et al. [15] but did not materialize industrially
to date.
Interestingly, we observed that the middle group of early experts
who were involved with the introduction of IVUS pointed at other
IVUS limitations than resolution. Certainly because, from their
perspective, IVUS filled a void in the interventional cardiology
space and entered as the highest resolution modality. On the
contrary, peripheral experts are likely to be involved to a lesser
extent with IVUS and potentially give a more positive judgment of
the advantages and disadvantages of IVUS technology. This
observation is in line with the concept of ‘‘certainty trough’’
developed by Donald A. MacKenzie [26], which states that
knowledge producers from a peripheral discipline attribute less
uncertainty to technology from another discipline than those
involved directly in knowledge production. More than resolution,
it is the ambiguity of IVUS images that the respondents
incriminate, telling us that understanding IVUS images requires
expertise. Whether a higher resolution will solve image interpre-
tation issues is not clear. Despite its microscopic resolution, OCT
is still in a phase of standardization, proven benefits have not been
demonstrated yet and the technology is not exempt of artifacts,
which makes OCT image interpretation an expert’s task as well.
Several respondents stressed the need for focused educational
programs in order to fully realize the potential of intracoronary
imaging techniques. They criticized the lack of exposure of
medical doctors to these techniques at resident stage. Educational
efforts in IVUS were considered as ‘‘hobbyist’’ by an early
European practitioner. And the relevance of educational efforts
was questioned by others given the poor penetration of IVUS.
When characterizing themselves, engineers declared a deficit in
clinical knowledge of IVUS compared to other groups, whereas
technical knowledge was homogeneously high among experts. A
more extensive education of engineers to the reality of IVUS
clinical procedures and catheter laboratory workflow might prove
to be critical for the successful introduction of future intracoronary
imaging modalities. Complementarily, educating interventional
cardiologists further in the physics of intravascular imaging could
improve patient treatment, by helping them to recognize image
artifacts and hence secure their diagnosis. It is likely that a more
substantial knowledge overlap between interventional cardiolo-
gists, biomedical engineers, industry leaders and investors would
accelerate IVUS innovation. The evolution of cardiac interven-
tions based on new medical technology was shown to be
progressing along co-evolving pathways: advances in scientific
understanding indeed, but more important improvements of the
ability to develop and use medical technologies as well as learning
in medical practice [27].
Most central experts in the network had a skeptical perception
of the potential for innovation that IVUS technology has left
(Figure 3). This can be understood from a historical perspective as
the field of IVUS faced a relative lack of IVUS innovation in the
past 20 year. 40 MHz IVUS was reported as early as 1991 in
scientific literature [20,21] and remains the standard product of
major IVUS companies today; image quality in IVUS did not
experience major breakthroughs in 20 years. Several respondents
criticized the lack of competition in the IVUS market, which
potentially stifles innovation. These respondents also called for the
creation of new start-ups to re-energize clinical translation. IVUS
companies happened to sit on innovation in some cases therefore
limiting the dissemination of new technological developments. It
was reported that patents have played a role, but that most of them
are now obsolete. Academic engineers were the only ones that
appeared clearly positive about the potential left for IVUS
innovation (Figure 2), probably because they envision potential
refinements in IVUS technology.
Given that five of the six identified controversies are external to
IVUS technology, we can hypothesize that decision making at the
industrial, financial and regulatory levels will orientate predom-
inantly future innovations in intracoronary imaging. As reported
earlier, a major conclusion is that opinion-leading cardiologists
and funders, who shape innovation to a large extent, disclosed a
pessimistic opinion of the existence of IVUS technology 20 years
from now. In general, minimally invasive imaging modalities are
logically not perceived as adequate for the early screening of
coronary atherosclerosis in asymptomatic patients. First, because
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the information they provide is local (as opposed to a full view of
the coronary anatomy e.g. angiography/MRI/CT) and second
because of their invasive character. Therefore, wide adoption of
intravascular imaging will depend on added benefits for cardiac
patients requiring intervention. If a medical consensus advocates
the identification of flow limiting lesions, then the combination of
fractional flow reserve (FFR) and angiography is sufficient [28]. If
medical guidelines state that the assessment of plaque vulnerability
is critical, then intravascular imaging techniques will play a role as
prognostic tools. In any case, next generation IVUS technologies
as well as new intravascular technologies will compete with OCT
in terms of image quality and guidance of stent apposition, and
with the combination of angiography and FFR in terms of clinical
decision making.
Conclusion
To date, IVUS remains valuable as it is the only clinical tool
capable of imaging plaque burden in vivo and because it is
grounded in extensive scientific literature. Mapping IVUS
controversies revealed that the appeal of intravascular ultrasound
may be renewed by improving (lateral) image resolution and/or
through combination with other imaging modalities. An integrated
IVUS-OCT catheter, providing OCT resolution and IVUS
penetration simultaneously, was recently evaluated in vivo [29].
This technical solution has the merit to solve the issue of IVUS
resolution. Other combined modalities were mentioned such as
NIRS-IVUS [30] and intravascular photoacoustics [31]. These
may provide an enhanced characterization of the arterial wall but
will still need to act on IVUS image quality. In all cases
miniaturization and integration of independent modalities will
weigh on cost-effectiveness.
The successful translation of future intravascular imaging
technologies in interventional cardiology practice will require a
rapid demonstration of clinical utility, which is a necessary
condition for an efficient reimbursement; otherwise, hospitals
cannot afford to use it. Finally, this must be coupled on a
willingness of care practitioners to gain experience in a range of
quickly developing technologies [32] in order to improve patient
care. Unless, of course, in the advent of preventive medicine, the
amount of percutaneous coronary interventions decreases drasti-
cally.
The future of IVUS as a stand-alone modality appears
uncertain due to a lack of demonstrated benefits of the technology
in terms of patient outcomes. Moreover, its use in cardiovascular
research is likely to erode with the emergence of newer
intravascular imaging techniques. As time passes, competition
among adjunctive interventional cardiology devices increases,
whereby the chance that IVUS will reach stand-alone reimburse-
ment decreases.
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